We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates
Read MoreHide Full Article
Patterson Companies, Inc. (PDCO - Free Report) reported adjusted earnings per share (EPS) of 32 cents for first-quarter fiscal 2023, which missed the Zacks Consensus Estimate of 38 cents by 15.8%. The bottom line decreased 25.6% from the prior-year quarter.
GAAP EPS in the quarter was 25 cents, down 28.6% from the prior-year quarter.
Revenue Details
Net sales in the quarter were $1.52 billion, which lagged the Zacks Consensus Estimate by 2.6%. The top line decreased 5.7% year over year.
Segmental Analysis
The company currently distributes products through subsidiaries — Patterson Dental and Patterson Animal Health.
Dental Segment
This segment provides a complete range of consumable dental products, equipment, software, turnkey digital solutions and value-added services to dentists and laboratories throughout North America.
In the fiscal first quarter, dental sales decreased 8.1% year over year to $557.9 million.
Dental Consumable
Sales in the sub-segment totaled $337.8 million, down 10.3% year over year.
Patterson Companies, Inc. Price, Consensus and EPS Surprise
Sales in the segment declined 6.7% on a year-over-year basis to $146.5 million.
Value-added Services and Other
This segment comprises technical service, parts and labor, software support services and office supplies. Sales at the segment fell 2.4% on a year-over-year basis to $87.6 million.
Animal Health Segment
This segment is a leading distributor of veterinary supplies to clinics, public and private institutions and shelters across the United States.
In the fiscal first quarter, the segment sales decreased 4.2% on a year-over-year basis to $960.3 million.
Corporate
Sales at the segment were $5 million compared with $5.2 million in the year-ago quarter.
Margin Analysis
Gross profit in the reported quarter was $312.1 million, up 12.4% year over year. As a percentage of revenues, the gross margin of 20.5% expanded approximately 330 basis points (bps) on a year-over-year basis.
Operating expenses in the reported quarter amounted to $277.3 million, down 12.6% from the prior-year quarter.
The company reported an operating income of $34.8 million against an operating loss of $39.5 million in the year-ago quarter.
Financial Position
The company exited the fiscal first quarter with cash and cash equivalents of $149.6 million, compared with $142 million on a sequential basis.
Cumulative net cash used in operating activities at the end of the fiscal first quarter was $302.5 million compared with the year-ago quarter’s net cash utilized in operating activities of $313.4 million.
Fiscal 2023 Earnings Outlook
Patterson Companies maintained its earnings outlook for fiscal 2023. The company projects adjusted EPS in the range of $2.25 to $2.35. The Zacks Consensus Estimate for the same is pegged at $2.30 per share.
Our Take
Patterson Companies ended first-quarter fiscal 2023 on a dismal note, wherein both earnings and revenues missed the consensus mark. The company also witnessed a decline in the performance of both its segments in the quarter under review, a key reason being currency movement. A prudent cost-savings approach and solid sales execution worked in favor of the stock, expanding gross margin. Sustained momentum in the Animal Health business bodes well.
A broad spectrum of products cushions the company against economic downturns in the MedTech space. We believe that a diverse product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are key catalysts.
Zacks Rank
Patterson Companies currently carries a Zacks Rank #2 (Buy).
Earnings of Other MedTech Majors at a Glance
Some stocks in the broader medical space that have announced quarterly results are Bio-Rad Laboratories, Inc. (BIO - Free Report) , AMN Healthcare Services, Inc. (AMN - Free Report) and McKesson (MCK - Free Report) .
Bio-Rad, carrying a Zacks Rank #2, reported second-quarter 2022 adjusted EPS of $3.38, which beat the Zacks Consensus Estimate by 37.4%. Revenues of $691 million outpaced the consensus mark by 3.9%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Bio-Rad has a historical earnings growth rate of 31.2%. BIO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 46.75%.
AMN Healthcare, sporting a Zacks Rank #1, reported second-quarter 2022 adjusted EPS of $3.31, which beat the Zacks Consensus Estimate by 11.8%. Revenues of $1.43 billion outpaced the consensus mark by 4.8%.
AMN Healthcare has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 15.66%.
McKesson reported fiscal first-quarter 2023 adjusted EPS of $5.83, which surpassed the Zacks Consensus Estimate by 9.8%. Revenues of $67.2 billion outpaced the Zacks Consensus Estimate by 5.2%. It currently has a Zacks Rank of 2.
McKesson has an earnings yield of 6.6% compared with the industry’s yield of 4.5%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 13%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates
Patterson Companies, Inc. (PDCO - Free Report) reported adjusted earnings per share (EPS) of 32 cents for first-quarter fiscal 2023, which missed the Zacks Consensus Estimate of 38 cents by 15.8%. The bottom line decreased 25.6% from the prior-year quarter.
GAAP EPS in the quarter was 25 cents, down 28.6% from the prior-year quarter.
Revenue Details
Net sales in the quarter were $1.52 billion, which lagged the Zacks Consensus Estimate by 2.6%. The top line decreased 5.7% year over year.
Segmental Analysis
The company currently distributes products through subsidiaries — Patterson Dental and Patterson Animal Health.
Dental Segment
This segment provides a complete range of consumable dental products, equipment, software, turnkey digital solutions and value-added services to dentists and laboratories throughout North America.
In the fiscal first quarter, dental sales decreased 8.1% year over year to $557.9 million.
Dental Consumable
Sales in the sub-segment totaled $337.8 million, down 10.3% year over year.
Patterson Companies, Inc. Price, Consensus and EPS Surprise
Patterson Companies, Inc. price-consensus-eps-surprise-chart | Patterson Companies, Inc. Quote
Dental Equipment & Software
Sales in the segment declined 6.7% on a year-over-year basis to $146.5 million.
Value-added Services and Other
This segment comprises technical service, parts and labor, software support services and office supplies. Sales at the segment fell 2.4% on a year-over-year basis to $87.6 million.
Animal Health Segment
This segment is a leading distributor of veterinary supplies to clinics, public and private institutions and shelters across the United States.
In the fiscal first quarter, the segment sales decreased 4.2% on a year-over-year basis to $960.3 million.
Corporate
Sales at the segment were $5 million compared with $5.2 million in the year-ago quarter.
Margin Analysis
Gross profit in the reported quarter was $312.1 million, up 12.4% year over year. As a percentage of revenues, the gross margin of 20.5% expanded approximately 330 basis points (bps) on a year-over-year basis.
Operating expenses in the reported quarter amounted to $277.3 million, down 12.6% from the prior-year quarter.
The company reported an operating income of $34.8 million against an operating loss of $39.5 million in the year-ago quarter.
Financial Position
The company exited the fiscal first quarter with cash and cash equivalents of $149.6 million, compared with $142 million on a sequential basis.
Cumulative net cash used in operating activities at the end of the fiscal first quarter was $302.5 million compared with the year-ago quarter’s net cash utilized in operating activities of $313.4 million.
Fiscal 2023 Earnings Outlook
Patterson Companies maintained its earnings outlook for fiscal 2023. The company projects adjusted EPS in the range of $2.25 to $2.35. The Zacks Consensus Estimate for the same is pegged at $2.30 per share.
Our Take
Patterson Companies ended first-quarter fiscal 2023 on a dismal note, wherein both earnings and revenues missed the consensus mark. The company also witnessed a decline in the performance of both its segments in the quarter under review, a key reason being currency movement. A prudent cost-savings approach and solid sales execution worked in favor of the stock, expanding gross margin. Sustained momentum in the Animal Health business bodes well.
A broad spectrum of products cushions the company against economic downturns in the MedTech space. We believe that a diverse product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are key catalysts.
Zacks Rank
Patterson Companies currently carries a Zacks Rank #2 (Buy).
Earnings of Other MedTech Majors at a Glance
Some stocks in the broader medical space that have announced quarterly results are Bio-Rad Laboratories, Inc. (BIO - Free Report) , AMN Healthcare Services, Inc. (AMN - Free Report) and McKesson (MCK - Free Report) .
Bio-Rad, carrying a Zacks Rank #2, reported second-quarter 2022 adjusted EPS of $3.38, which beat the Zacks Consensus Estimate by 37.4%. Revenues of $691 million outpaced the consensus mark by 3.9%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Bio-Rad has a historical earnings growth rate of 31.2%. BIO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 46.75%.
AMN Healthcare, sporting a Zacks Rank #1, reported second-quarter 2022 adjusted EPS of $3.31, which beat the Zacks Consensus Estimate by 11.8%. Revenues of $1.43 billion outpaced the consensus mark by 4.8%.
AMN Healthcare has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 15.66%.
McKesson reported fiscal first-quarter 2023 adjusted EPS of $5.83, which surpassed the Zacks Consensus Estimate by 9.8%. Revenues of $67.2 billion outpaced the Zacks Consensus Estimate by 5.2%. It currently has a Zacks Rank of 2.
McKesson has an earnings yield of 6.6% compared with the industry’s yield of 4.5%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 13%.